medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 3

<< Back Next >>

Ann Hepatol 2004; 3 (3)

Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial

Méndez-Sánchez N, González V, Chávez-Tapia N, Ramos MH, Uribe M

Language: English
References: 31
Page: 108-112
PDF size: 44.05 Kb.


Text Extraction

Objetive: Nonalcoholic fatty liver disease is an increasingly recognized condition that may progress to endstage liver disease. We investigated the effects of weight reduction and ursodeoxycholic acid administration in patients with this disease.
Research methods and procedures: A double-blind, placebo-controlled trial.
Twenty-seven women with a body mass index of ›30 kg/m2 and willing to participate in the diet plan for six weeks were studied were assigned to one of two treatment groups (ursodeoxycholic acid, n = 14: placebo n = 13). Both groups received a normal diet (1,200 kcal/d) plus 1200 mg/d of ursodeoxycholic acid or placebo. Hepatic steatosis, was assessed by abdominal ultrasound. Fasting glucose, cholesterol, triglycerides, and aminotransferases levels were detrmined before and after treatment.
Results: Body mass index decreases significantly from 34.2 ± 4.2 kg/m2 and 33.3 ± 1.6 kg/m2 to 31.8 ± 4.5 kg/m2 and 30.6 ± 2.6 kg/m2 in the ursodeoxycholic acid and placebo groups, p ‹ 0.001. The hepatic steatosis index decreased from 2.3 ± 0.7 to 1.0 ± 0.6 and 2.2 ± 0.7 to 1.1 ± 0.7 in the ursodeoxycholic acid and placebo groups, p‹0.003. Serum AST decreased significantly from 41.2 ± 5.6 to 34.5 ± 3.4 in the ursodeoxycholic acid group, p ‹0.001, and from 43.6 ± 4.2 to 35.3 ± 2.9 in the placebo group, p ‹0.001. Serum ALT decreased from 62.9 ± 6.5 to 44.0 ± 3.5 in the ursodeoxycholic acid group, p ‹0.001, and from 63.5 ± 4.5 to 44.0 ± 3.5 in the placebo group. We did not find any differences in all variables studied between groups.
Conclusions: The present study shows beneficial effect of weight reduction, producing improvements in biochemical and imaging markers of liver disease.


REFERENCES

  1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.

  2. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8: 283-298.

  3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.

  4. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995; 10: 414-421.

  5. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413.

  6. Angulo P. Treatment of nonalcoholic fatty liver disease. Ann Hepatol 2001; 1: 12-19.

  7. Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, Hamasaki K, Kato Y, Eguchi K, Yukawa K, Ishii N. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002; 97: 1796-1801.

  8. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002; 16: 703-716.

  9. Herbert T, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-1476.

  10. Hofmann AF. Bile Acids: The Good, the Bad, and the Ugly. News Physiol Sci 1999; 14: 24-29.

  11. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.

  12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifugation. Clin Chem 1972; 18: 499-502.

  13. Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill; 1971.

  14. Agrawal S, Bonkovsky HL. Management of nonalcoholic steatohepatitis: an analytic review. J Clin Gastroenterol 2002; 35: 253-261.

  15. Fan J, Zhong L, Wang G, Tian L, Wu W, Li M. Influence of ursodeoxycholic acid on the therapeutic effects of low-calorie diet in obesity and hyperlipidemia rats with steatohepatitis. Zhonghua Gan Zang Bing Za Zhi 2002; 10: 43-45.

  16. Lukivskaya OY, Maskevich AA, Buko VU. Effect of ursodeoxycholic acid on prostaglandin metabolism and microsomal membranes in alcoholic fatty liver. Alcohol 2001; 25: 99-105.

  17. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075.

  18. Simon E, del Puy Portillo M, Fernandez-Quintela A, Zulet MA, Martinez JA, Del Barrio AS. Responses to dietary macronutrient distribution of overweight rats under restricted feeding. Ann Nutr Metab 2002; 46: 24-31.

  19. Tornquist SJ, Cebra CK, Van Saun RJ, Smith BB, Mattoon JS. Metabolic changes and induction of hepatic lipidosis during feed restriction in llamas. Am J Vet Res 2001; 62: 1081-1087.

  20. Szabo J, Ibrahim WH, Sunvold GD, Dickey KM, Rodgers JB, Toth IE, Boissonneault GA, Bruckner GG. Influence of dietary protein and lipid on weight loss in obese ovariohysterectomized cats. Am J Vet Res 2000; 61: 559-565.

  21. Ibrahim WH, Szabo J, Sunvold GD, Kelleher JK, Bruckner GG. Effect of dietary protein quality and fatty acid composition on plasma lipoprotein concentrations and hepatic triglyceride fatty acid synthesis in obese cats undergoing rapid weight loss. Am J Vet Res 2000; 61: 566-572.

  22. Brown B, Mauldin GE, Armstrong J, Moroff SD, Mauldin GN. Metabolic and hormonal alterations in cats with hepatic lipidosis. J Vet Intern Med 2000; 14: 20-26.

  23. Biourge V, Nelson RW, Feldman EC, Willits NH, Morris JG, Rogers QR. Effect of weight gain and subsequent weight loss on glucose tolerance and insulin response in healthy cats. J Vet Intern Med 1997; 11: 86-91.

  24. Case CC, Jones PH, Nelson K, O’Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002; 4: 407-414.

  25. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001; 7: S13-S21.

  26. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.

  27. Busetto L, Tregnaghi A, De Marchi F, et al. Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res 2002; 10: 408-411.

  28. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998 ;22: 222-226.

  29. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.

  30. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the Marked increases in hepatic iron concentrations clearly treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-1467.

  31. Santos VN, Lanzoni VP, Szejnfeld J, Shigueoka D, Parise ER. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res 2003; 36: 723-9.




2020     |     www.medigraphic.com